speb/financial-data huggingface dataset:
PCRX.V cash_flow (annual, 2022-12-31) — Common Stock Issuance: 2000000.00
PCRX.V balance_sheet (annual, 2022-12-31) — Current Assets: 2733379.00
PCRX.V balance_sheet (annual, 2022-12-31) — Current Deferred Assets: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Current Liabilities: 16465.00
PCRX.V income_statement (annual, 2022-12-31) — Diluted Average Shares: 32547945.00
PCRX.V income_statement (annual, 2022-12-31) — Diluted EPS: -0.02
PCRX.V income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — EBIT: -563177.00
PCRX.V income_statement (annual, 2022-12-31) — EBITDA: -563177.00
PCRX.V cash_flow (annual, 2022-12-31) — End Cash Position: 2733379.00
PCRX.V cash_flow (annual, 2022-12-31) — Financing Cash Flow: 1873537.00
PCRX.V cash_flow (annual, 2022-12-31) — Free Cash Flow: -120183.00
PCRX.V income_statement (annual, 2022-12-31) — General And Administrative Expense: 563177.00
PCRX.V income_statement (annual, 2022-12-31) — Interest Income: 46092.00
PCRX.V income_statement (annual, 2022-12-31) — Interest Income Non Operating: 46092.00
PCRX.V cash_flow (annual, 2022-12-31) — Interest Paid Cff: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Invested Capital: 2716914.00
PCRX.V cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 2000000.00
PCRX.V cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 2000000.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -517085.00
PCRX.V cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -517085.00
PCRX.V income_statement (annual, 2022-12-31) — Net Interest Income: 46092.00
PCRX.V income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 46092.00
PCRX.V cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -126463.00
PCRX.V balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 2716914.00
PCRX.V income_statement (annual, 2022-12-31) — Normalized EBITDA: -563177.00
PCRX.V income_statement (annual, 2022-12-31) — Normalized Income: -517085.00
PCRX.V cash_flow (annual, 2022-12-31) — Operating Cash Flow: -120183.00
PCRX.V income_statement (annual, 2022-12-31) — Operating Income: -563177.00
PCRX.V income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 40000000.00
PCRX.V income_statement (annual, 2022-12-31) — Other Gand A: 176897.00
PCRX.V balance_sheet (annual, 2022-12-31) — Payables: 16465.00
PCRX.V balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 16465.00
PCRX.V income_statement (annual, 2022-12-31) — Pretax Income: -517085.00
PCRX.V balance_sheet (annual, 2022-12-31) — Retained Earnings: -542903.00
PCRX.V income_statement (annual, 2022-12-31) — Salaries And Wages: 386280.00
PCRX.V income_statement (annual, 2022-12-31) — Selling General And Administration: 563177.00
PCRX.V balance_sheet (annual, 2022-12-31) — Share Issued: 40000000.00
PCRX.V cash_flow (annual, 2022-12-31) — Stock Based Compensation: 386280.00
PCRX.V balance_sheet (annual, 2022-12-31) — Stockholders Equity: 2716914.00
PCRX.V balance_sheet (annual, 2022-12-31) — Tangible Book Value: 2716914.00
PCRX.V income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Assets: 2733379.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Capitalization: 2716914.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 2716914.00
PCRX.V income_statement (annual, 2022-12-31) — Total Expenses: 563177.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 16465.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
PCRX.V balance_sheet (annual, 2022-12-31) — Working Capital: 2716914.00
PCRX.V income_statement (annual, 2023-12-31) — +Operating Expense: 577960.00
PCRX.V income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Accounts Payable: 46185.00
PCRX.V balance_sheet (annual, 2023-12-31) — Accounts Receivable: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 488792.00
PCRX.V income_statement (annual, 2023-12-31) — Basic Average Shares: 40278400.00
PCRX.V income_statement (annual, 2023-12-31) — Basic EPS: -0.01
PCRX.V cash_flow (annual, 2023-12-31) — Beginning Cash Position: 2733379.00
PCRX.V balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Capital Stock: 2798865.00
PCRX.V balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 2241761.00
PCRX.V balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 2241761.00
PCRX.V balance_sheet (annual, 2023-12-31) — Cash Financial: 2241761.00
PCRX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 27840.00
PCRX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -519458.00
PCRX.V cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -78750.00
PCRX.V cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 29720.00
PCRX.V cash_flow (annual, 2023-12-31) — Change In Working Capital: -49030.00
PCRX.V cash_flow (annual, 2023-12-31) — Changes In Cash: -491618.00
PCRX.V balance_sheet (annual, 2023-12-31) — Common Stock: 2798865.00
PCRX.V balance_sheet (annual, 2023-12-31) — Common Stock Equity: 2274326.00
PCRX.V cash_flow (annual, 2023-12-31) — Common Stock Issuance: 27840.00
PCRX.V income_statement (annual, 2023-12-31) — Cost Of Revenue: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Current Assets: 2320511.00
PCRX.V balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Current Deferred Assets: 78750.00
PCRX.V balance_sheet (annual, 2023-12-31) — Current Liabilities: 46185.00
PCRX.V cash_flow (annual, 2023-12-31) — Deferred Income Tax: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Deferred Tax: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Depreciation Income Statement: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Diluted Average Shares: 40278400.00
PCRX.V income_statement (annual, 2023-12-31) — Diluted EPS: -0.01
PCRX.V income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — EBIT: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — EBITDA: -470428.00
PCRX.V cash_flow (annual, 2023-12-31) — End Cash Position: 2241761.00
PCRX.V cash_flow (annual, 2023-12-31) — Financing Cash Flow: 27840.00
PCRX.V cash_flow (annual, 2023-12-31) — Free Cash Flow: -519458.00
PCRX.V income_statement (annual, 2023-12-31) — General And Administrative Expense: 577960.00
PCRX.V balance_sheet (annual, 2023-12-31) — Goodwill: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Gross PPE: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Gross Profit: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Interest Expense: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Interest Income: 107532.00
PCRX.V income_statement (annual, 2023-12-31) — Interest Income Non Operating: 107532.00
PCRX.V balance_sheet (annual, 2023-12-31) — Inventory: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Invested Capital: 2274326.00
PCRX.V cash_flow (annual, 2023-12-31) — Investing Cash Flow: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 27840.00
PCRX.V balance_sheet (annual, 2023-12-31) — Land And Improvements: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Leases: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Minority Interest: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 27840.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -470428.00
PCRX.V cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Net Interest Income: 107532.00
PCRX.V cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 107532.00
PCRX.V balance_sheet (annual, 2023-12-31) — Net PPE: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 2274326.00
PCRX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Normalized EBITDA: -470428.00
PCRX.V income_statement (annual, 2023-12-31) — Normalized Income: -470428.00
PCRX.V cash_flow (annual, 2023-12-31) — Operating Cash Flow: -519458.00
PCRX.V income_statement (annual, 2023-12-31) — Operating Income: -577960.00
PCRX.V income_statement (annual, 2023-12-31) — Operating Revenue: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 40278400.00
PCRX.V income_statement (annual, 2023-12-31) — Other Gand A: 577960.00
PCRX.V balance_sheet (annual, 2023-12-31) — Payables: 46185.00
PCRX.V balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 46185.00
PCRX.V balance_sheet (annual, 2023-12-31) — Prepaid Assets: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Pretax Income: -470428.00
PCRX.V cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Properties: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Purchase Of PPE: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Raw Materials: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Receivables: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Reconciled Depreciation: 0.00
PCRX.V cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Retained Earnings: -1013331.00
PCRX.V income_statement (annual, 2023-12-31) — Salaries And Wages: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Selling General And Administration: 577960.00
PCRX.V balance_sheet (annual, 2023-12-31) — Share Issued: 40278400.00
PCRX.V cash_flow (annual, 2023-12-31) — Stock Based Compensation: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Stockholders Equity: 2274326.00
PCRX.V balance_sheet (annual, 2023-12-31) — Tangible Book Value: 2274326.00
PCRX.V income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Tax Provision: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Assets: 2320511.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Capitalization: 2274326.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Debt: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 2274326.00
PCRX.V income_statement (annual, 2023-12-31) — Total Expenses: 577960.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 46185.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
PCRX.V income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -577960.00
PCRX.V balance_sheet (annual, 2023-12-31) — Total Tax Payable: 0.00
PCRX.V balance_sheet (annual, 2023-12-31) — Working Capital: 2274326.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Amortization Cash Flow: 31208.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Amortization Of Intangibles: 31208.00
PCRX.V income_statement (quarterly, 2024-09-30) — Basic Average Shares: 113157839.00
PCRX.V income_statement (quarterly, 2024-09-30) — Basic EPS: -0.01
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Account Payable: -96340.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Income Tax Payable: -9300.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Inventory: -134062.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Other Working Capital: 0.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Payable: -223886.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Payables And Accrued Expense: -223886.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Prepaid Assets: -42474.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Receivables: -77505.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Change In Tax Payable: -9300.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Changes In Account Receivables: -96923.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Common Stock Issuance: 7635713.00
PCRX.V balance_sheet (quarterly, 2024-09-30) — Current Deferred Assets: 0.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Depreciation: 44675.00
PCRX.V income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 113157839.00
PCRX.V income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.01
PCRX.V cash_flow (quarterly, 2024-09-30) — Issuance Of Capital Stock: 7635713.00
PCRX.V income_statement (quarterly, 2024-09-30) — Minority Interests: 1760.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Net Business Purchase And Sale: -2084114.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Net Common Stock Issuance: 7635713.00
PCRX.V cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
PCRX.V balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 228.00
PCRX.V income_statement (annual, 2024-12-31) — +Operating Expense: 3772695.00
PCRX.V income_statement (quarterly, 2024-12-31) — +Operating Expense: 1312107.00
PCRX.V income_statement (annual, 2024-12-31) — +Total Revenue: 5794914.00
PCRX.V income_statement (quarterly, 2024-12-31) — +Total Revenue: 4399075.00
PCRX.V balance_sheet (annual, 2024-12-31) — Accounts Payable: 1536268.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 1536268.00
PCRX.V balance_sheet (annual, 2024-12-31) — Accounts Receivable: 326783.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 326783.00
PCRX.V balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -69779.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -69779.00
PCRX.V balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 674733.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Additional Paid In Capital: 674733.00
PCRX.V income_statement (annual, 2024-12-31) — Basic Average Shares: 81725268.00
PCRX.V income_statement (annual, 2024-12-31) — Basic EPS: -0.01
PCRX.V cash_flow (annual, 2024-12-31) — Beginning Cash Position: 2241761.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Beginning Cash Position: 26676588.00
PCRX.V balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 3387671.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 3387671.00
PCRX.V cash_flow (annual, 2024-12-31) — Capital Expenditure: -6890.00
PCRX.V balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 559459.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 559459.00
PCRX.V balance_sheet (annual, 2024-12-31) — Capital Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Capital Stock: 31695204.00
PCRX.V balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 12886556.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 12886556.00
PCRX.V balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 12886556.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 12886556.00
PCRX.V balance_sheet (annual, 2024-12-31) — Cash Financial: 12886556.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Cash Financial: 12886556.00
PCRX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 27384158.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Financing Activities: -51053.00
PCRX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -16864331.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Investing Activities: -14853540.00
PCRX.V cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 124968.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Cash Flow From Continuing Operating Activities: 1114562.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Account Payable: 498425.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Income Tax Payable: 2920.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Inventory: 111300.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 78750.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Payable: 501345.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 501345.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -1317.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Receivables: 18000.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Tax Payable: 2920.00
PCRX.V cash_flow (annual, 2024-12-31) — Change In Working Capital: 708078.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Change In Working Capital: 761020.00
PCRX.V cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -538.00
PCRX.V cash_flow (annual, 2024-12-31) — Changes In Cash: 10644795.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Changes In Cash: -13790032.00
PCRX.V balance_sheet (annual, 2024-12-31) — Common Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Common Stock: 31695204.00
PCRX.V balance_sheet (annual, 2024-12-31) — Common Stock Equity: 30343781.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 30343781.00
PCRX.V cash_flow (annual, 2024-12-31) — Common Stock Issuance: 27327975.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Common Stock Issuance: 0.00
PCRX.V income_statement (annual, 2024-12-31) — Cost Of Revenue: 3610552.00
PCRX.V income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 2728801.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Assets: 14574404.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Assets: 14574404.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 73972.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 73972.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Debt: 75412.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Debt: 75412.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 149384.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 149384.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Deferred Assets: 0.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Deferred Assets: 0.00
PCRX.V balance_sheet (annual, 2024-12-31) — Current Liabilities: 1696173.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 1696173.00
PCRX.V cash_flow (annual, 2024-12-31) — Deferred Income Tax: -137637.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Deferred Income Tax: -127419.00
PCRX.V cash_flow (annual, 2024-12-31) — Deferred Tax: -137637.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Deferred Tax: -127419.00
PCRX.V cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 289874.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 191563.00
PCRX.V income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 289874.00
PCRX.V income_statement (quarterly, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 191563.00
PCRX.V cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 289874.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 191563.00
PCRX.V income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 289874.00
PCRX.V income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 191563.00
PCRX.V income_statement (annual, 2024-12-31) — Depreciation Income Statement: 289874.00
PCRX.V income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 230121.00
PCRX.V income_statement (annual, 2024-12-31) — Diluted Average Shares: 81725268.00
PCRX.V income_statement (annual, 2024-12-31) — Diluted EPS: -0.01
PCRX.V income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 721210.00
PCRX.V income_statement (annual, 2024-12-31) — EBIT: -1124952.00
PCRX.V income_statement (quarterly, 2024-12-31) — EBIT: 630599.00
PCRX.V income_statement (annual, 2024-12-31) — EBITDA: -835078.00
PCRX.V income_statement (quarterly, 2024-12-31) — EBITDA: 822162.00
PCRX.V cash_flow (annual, 2024-12-31) — End Cash Position: 12886556.00
PCRX.V cash_flow (quarterly, 2024-12-31) — End Cash Position: 12886556.00
PCRX.V cash_flow (annual, 2024-12-31) — Financing Cash Flow: 27384158.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Financing Cash Flow: -51053.00
PCRX.V cash_flow (annual, 2024-12-31) — Free Cash Flow: 118078.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Free Cash Flow: 1114561.00
PCRX.V income_statement (annual, 2024-12-31) — General And Administrative Expense: 3482821.00
PCRX.V income_statement (quarterly, 2024-12-31) — General And Administrative Expense: 1120544.00
PCRX.V balance_sheet (annual, 2024-12-31) — Goodwill: 11476170.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Goodwill: 11476170.00
PCRX.V balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 16609957.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Goodwill And Other Intangible Assets: 16609957.00
PCRX.V balance_sheet (annual, 2024-12-31) — Gross PPE: 4094460.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Gross PPE: 4094460.00
PCRX.V income_statement (annual, 2024-12-31) — Gross Profit: 2184362.00
PCRX.V income_statement (quarterly, 2024-12-31) — Gross Profit: 1670274.00
PCRX.V income_statement (annual, 2024-12-31) — Interest Expense: 32434.00
PCRX.V income_statement (quarterly, 2024-12-31) — Interest Expense: 14396.00
PCRX.V income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 32434.00
PCRX.V income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 14396.00
PCRX.V income_statement (annual, 2024-12-31) — Interest Income: 381248.00
PCRX.V income_statement (quarterly, 2024-12-31) — Interest Income: 191499.00
PCRX.V income_statement (annual, 2024-12-31) — Interest Income Non Operating: 381248.00
PCRX.V income_statement (quarterly, 2024-12-31) — Interest Income Non Operating: 191499.00
PCRX.V balance_sheet (annual, 2024-12-31) — Inventory: 1313039.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Inventory: 1313039.00
PCRX.V balance_sheet (annual, 2024-12-31) — Invested Capital: 30737399.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Invested Capital: 30737399.00
PCRX.V cash_flow (annual, 2024-12-31) — Investing Cash Flow: -16864331.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Investing Cash Flow: -14853540.00
PCRX.V cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 27327975.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: 0.00
PCRX.V cash_flow (annual, 2024-12-31) — Issuance Of Debt: 0.00
PCRX.V balance_sheet (annual, 2024-12-31) — Land And Improvements: 270275.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 270275.00
PCRX.V balance_sheet (annual, 2024-12-31) — Leases: 309067.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Leases: 309067.00
PCRX.V balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 485487.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 485487.00
PCRX.V balance_sheet (annual, 2024-12-31) — Long Term Debt: 318206.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Long Term Debt: 318206.00
PCRX.V balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 803693.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 803693.00
PCRX.V cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 0.00
PCRX.V cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -107077.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: -51053.00
PCRX.V balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 127447.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 127447.00
PCRX.V balance_sheet (annual, 2024-12-31) — Minority Interest: 222483.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Minority Interest: 222483.00
PCRX.V cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -16857441.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: -14853540.00
PCRX.V cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 27327975.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net Common Stock Issuance: 0.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income: 721210.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 721210.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 723233.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 721210.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 721210.00
PCRX.V cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -1050935.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net Income From Continuing Operations: 723233.00
PCRX.V income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 723233.00
PCRX.V income_statement (annual, 2024-12-31) — Net Interest Income: 348814.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Interest Income: 177103.00
PCRX.V cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -107077.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net Issuance Payments Of Debt: -51053.00
PCRX.V cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -107077.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: -51053.00
PCRX.V income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 348814.00
PCRX.V income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: 177103.00
PCRX.V balance_sheet (annual, 2024-12-31) — Net PPE: 4024681.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Net PPE: 4024681.00
PCRX.V cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -6890.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: 0.00
PCRX.V balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 13733824.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 13733824.00
PCRX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 2142912.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Liabilities: 2142912.00
PCRX.V balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 2142912.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Taxes Liabilities: 2142912.00
PCRX.V income_statement (annual, 2024-12-31) — Normalized EBITDA: -835078.00
PCRX.V income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 822162.00
PCRX.V income_statement (annual, 2024-12-31) — Normalized Income: -1050935.00
PCRX.V income_statement (quarterly, 2024-12-31) — Normalized Income: 721210.00
PCRX.V cash_flow (annual, 2024-12-31) — Operating Cash Flow: 124968.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Operating Cash Flow: 1114561.00
PCRX.V income_statement (annual, 2024-12-31) — Operating Income: -1588333.00
PCRX.V income_statement (quarterly, 2024-12-31) — Operating Income: 358167.00
PCRX.V income_statement (annual, 2024-12-31) — Operating Revenue: 5731681.00
PCRX.V income_statement (quarterly, 2024-12-31) — Operating Revenue: 4399075.00
PCRX.V balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 117295525.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 117295525.00
PCRX.V balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 75412.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Other Current Borrowings: 75412.00
PCRX.V income_statement (annual, 2024-12-31) — Other Gand A: 1883032.00
PCRX.V income_statement (quarterly, 2024-12-31) — Other Gand A: 700859.00
PCRX.V income_statement (annual, 2024-12-31) — Other Income Expense: 82133.00
PCRX.V income_statement (quarterly, 2024-12-31) — Other Income Expense: 80933.00
PCRX.V balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 5133787.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Other Intangible Assets: 5133787.00
PCRX.V balance_sheet (annual, 2024-12-31) — Other Inventories: 1268785.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Other Inventories: 1268785.00
PCRX.V cash_flow (annual, 2024-12-31) — Other Non Cash Items: 32434.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: 14395.00
PCRX.V balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: -1000.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Other Non Current Liabilities: -1000.00
PCRX.V income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 82133.00
PCRX.V income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 80933.00
PCRX.V balance_sheet (annual, 2024-12-31) — Payables: 1546789.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Payables: 1546789.00
PCRX.V balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 1546789.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Payables And Accrued Expenses: 1546789.00
PCRX.V balance_sheet (annual, 2024-12-31) — Prepaid Assets: 48026.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 48026.00
PCRX.V income_statement (annual, 2024-12-31) — Pretax Income: -1157386.00
PCRX.V income_statement (quarterly, 2024-12-31) — Pretax Income: 616203.00
PCRX.V cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 163260.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
PCRX.V balance_sheet (annual, 2024-12-31) — Properties: 0.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
PCRX.V cash_flow (annual, 2024-12-31) — Purchase Of Business: -16857441.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Purchase Of Business: -14853540.00
PCRX.V cash_flow (annual, 2024-12-31) — Purchase Of PPE: -6890.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: 0.00
PCRX.V balance_sheet (annual, 2024-12-31) — Raw Materials: 44254.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Raw Materials: 44254.00
PCRX.V balance_sheet (annual, 2024-12-31) — Receivables: 326783.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Receivables: 326783.00
PCRX.V income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 3610552.00
PCRX.V income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 2728801.00
PCRX.V income_statement (annual, 2024-12-31) — Reconciled Depreciation: 289874.00
PCRX.V income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 191563.00
PCRX.V cash_flow (annual, 2024-12-31) — Repayment Of Debt: -107077.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: -51053.00
PCRX.V balance_sheet (annual, 2024-12-31) — Retained Earnings: -2026156.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -2026156.00
PCRX.V income_statement (annual, 2024-12-31) — Salaries And Wages: 1599789.00
PCRX.V income_statement (quarterly, 2024-12-31) — Salaries And Wages: 419685.00
PCRX.V income_statement (annual, 2024-12-31) — Selling General And Administration: 3482821.00
PCRX.V income_statement (quarterly, 2024-12-31) — Selling General And Administration: 1120544.00
PCRX.V balance_sheet (annual, 2024-12-31) — Share Issued: 117295525.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Share Issued: 117295525.00
PCRX.V cash_flow (annual, 2024-12-31) — Stock Based Compensation: 283154.00
PCRX.V cash_flow (quarterly, 2024-12-31) — Stock Based Compensation: -448231.00
PCRX.V balance_sheet (annual, 2024-12-31) — Stockholders Equity: 30343781.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 30343781.00
PCRX.V balance_sheet (annual, 2024-12-31) — Tangible Book Value: 13733824.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 13733824.00
PCRX.V income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (annual, 2024-12-31) — Tax Provision: -106451.00
PCRX.V income_statement (quarterly, 2024-12-31) — Tax Provision: -107030.00
PCRX.V income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.09
PCRX.V income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.15
PCRX.V balance_sheet (annual, 2024-12-31) — Total Assets: 35209042.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Assets: 35209042.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Capitalization: 30661987.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 30661987.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Debt: 953077.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Debt: 953077.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 30566264.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 30566264.00
PCRX.V income_statement (annual, 2024-12-31) — Total Expenses: 7383247.00
PCRX.V income_statement (quarterly, 2024-12-31) — Total Expenses: 4040908.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 4642778.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 4642778.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 20634638.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 20634638.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2946605.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2946605.00
PCRX.V income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -1602593.00
PCRX.V income_statement (quarterly, 2024-12-31) — Total Operating Income As Reported: 352218.00
PCRX.V balance_sheet (annual, 2024-12-31) — Total Tax Payable: 10521.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 10521.00
PCRX.V balance_sheet (annual, 2024-12-31) — Working Capital: 12878231.00
PCRX.V balance_sheet (quarterly, 2024-12-31) — Working Capital: 12878231.00
PCRX.V income_statement (quarterly, 2025-03-31) — +Operating Expense: 1395849.00
PCRX.V income_statement (quarterly, 2025-03-31) — +Total Revenue: 4006957.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 1440643.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 372437.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -106450.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 674733.00
PCRX.V income_statement (quarterly, 2025-03-31) — Amortization: 128343.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Amortization Cash Flow: 128343.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Amortization Of Intangibles: 128343.00
PCRX.V income_statement (quarterly, 2025-03-31) — Amortization Of Intangibles Income Statement: 128343.00
PCRX.V income_statement (quarterly, 2025-03-31) — Basic Average Shares: 117295525.00
PCRX.V income_statement (quarterly, 2025-03-31) — Basic EPS: 0.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 12886556.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 3365226.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -26903.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 541347.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Capital Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 12938515.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 12938515.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Cash Financial: 12938515.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -50672.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -26903.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 129534.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -95625.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: 141971.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Inventory: -308484.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Payable: 46346.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 46346.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 15873.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Receivables: -45654.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: 141971.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -291919.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -45654.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Changes In Cash: 51959.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Common Stock: 31695204.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 30585693.00
PCRX.V income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2382942.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Current Assets: 14964628.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 75069.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Current Debt: 75412.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 150481.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1743616.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -34011.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Deferred Tax: -34011.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Depreciation: 59116.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 187459.00
PCRX.V income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 187459.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 187459.00
PCRX.V income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 187459.00
PCRX.V income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 187459.00
PCRX.V income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 125160525.00
PCRX.V income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.00
PCRX.V income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 241913.00
PCRX.V income_statement (quarterly, 2025-03-31) — EBIT: 375735.00
PCRX.V income_statement (quarterly, 2025-03-31) — EBITDA: 563194.00
PCRX.V cash_flow (quarterly, 2025-03-31) — End Cash Position: 12938515.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -50672.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 102631.00
PCRX.V income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 1208390.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Goodwill: 11476170.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 16481614.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Gross PPE: 4098918.00
PCRX.V income_statement (quarterly, 2025-03-31) — Gross Profit: 1624015.00
PCRX.V income_statement (quarterly, 2025-03-31) — Interest Expense: 13706.00
PCRX.V income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 13706.00
PCRX.V income_statement (quarterly, 2025-03-31) — Interest Income: 104328.00
PCRX.V income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 104328.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Inventory: 1621523.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Invested Capital: 30960458.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -26903.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 270275.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Leases: 309067.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 466278.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 299353.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 765631.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -50672.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 154350.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Minority Interest: 234869.00
PCRX.V income_statement (quarterly, 2025-03-31) — Minority Interests: -12386.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income: 241913.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 241913.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 254299.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 241913.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 241913.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 254299.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 254299.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Interest Income: 90622.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -50672.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -50672.00
PCRX.V income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 90622.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Net PPE: 3992468.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -26903.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 14104079.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 2108901.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 2108901.00
PCRX.V income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 563194.00
PCRX.V income_statement (quarterly, 2025-03-31) — Normalized Income: 241913.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 129534.00
PCRX.V income_statement (quarterly, 2025-03-31) — Operating Income: 228166.00
PCRX.V income_statement (quarterly, 2025-03-31) — Operating Revenue: 3966890.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 117295525.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 75412.00
PCRX.V income_statement (quarterly, 2025-03-31) — Other Gand A: 379760.00
PCRX.V income_statement (quarterly, 2025-03-31) — Other Income Expense: 43241.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 5005444.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 13706.00
PCRX.V income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 43241.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Payables: 1593135.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 1593135.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 32153.00
PCRX.V income_statement (quarterly, 2025-03-31) — Pretax Income: 362029.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Purchase Of Business: 0.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -26903.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Receivables: 372437.00
PCRX.V income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2382942.00
PCRX.V income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 187459.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -50672.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1784244.00
PCRX.V income_statement (quarterly, 2025-03-31) — Salaries And Wages: 828630.00
PCRX.V income_statement (quarterly, 2025-03-31) — Selling General And Administration: 1208390.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Share Issued: 117295525.00
PCRX.V cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 0.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 30585693.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 14104079.00
PCRX.V income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
PCRX.V income_statement (quarterly, 2025-03-31) — Tax Provision: 107730.00
PCRX.V income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.30
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Assets: 35438710.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 30885046.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Debt: 916112.00
PCRX.V balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 30820562.00
PCRX.V income_statement (quarterly, 2025-03-31) — Total Expenses: 3778791.00